Biogen Inc. Common Stock (BIIB)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Biogen Inc. Common Stock (BIIB)
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Key Insights
Critical company metrics and information
Share Price
$157.78Market Cap
$22.99 BillionTotal Outstanding Shares
145.72 Million SharesTotal Employees
7,570Dividend
No dividendIPO Date
September 17, 1991SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.biogen.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $-643.30 Million |
Net Cash Flow From Investing Activities | $-1.43 Billion |
Net Cash Flow | $-588.70 Million |
Net Cash Flow From Financing Activities, Continuing | $-1.34 Billion |
Net Cash Flow From Operating Activities | $2.13 Billion |
Net Cash Flow From Operating Activities, Continuing | $2.13 Billion |
Exchange Gains/Losses | $54.60 Million |
Net Cash Flow From Investing Activities, Continuing | $-1.43 Billion |
Net Cash Flow From Financing Activities | $-1.34 Billion |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Revenues | $9.61 Billion |
Income/Loss From Continuing Operations Before Tax | $1.91 Billion |
Selling, General, and Administrative Expenses | $2.33 Billion |
Income Tax Expense/Benefit, Deferred | $-27.80 Million |
Income/Loss From Continuing Operations After Tax | $1.61 Billion |
Income Tax Expense/Benefit | $291.70 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $800000.00 |
Operating Income/Loss | $1.91 Billion |
Gross Profit | $7.26 Billion |
Basic Earnings Per Share | $11.10 |
Diluted Earnings Per Share | $11.06 |
Net Income/Loss | $1.61 Billion |
Other Operating Expenses | $3.02 Billion |
Cost Of Revenue | $2.35 Billion |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Basic Average Shares | $145.50 Million |
Interest Expense, Operating | $261.80 Million |
Costs And Expenses | $7.70 Billion |
Diluted Average Shares | $146.10 Million |
Benefits Costs and Expenses | $7.70 Billion |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss Attributable To Parent | $1.62 Billion |
Operating Expenses | $5.36 Billion |
Net Income/Loss Available To Common Stockholders, Basic | $1.62 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Current Assets | $4.36 Billion |
Long-term Debt | $4.55 Billion |
Equity Attributable To Parent | $16.36 Billion |
Noncurrent Assets | $21.48 Billion |
Intangible Assets | $9.81 Billion |
Other Non-current Liabilities | $1.98 Billion |
Accounts Payable | $422.70 Million |
Wages | $288.70 Million |
Current Liabilities | $5.42 Billion |
Inventory | $2.47 Billion |
Fixed Assets | $3.21 Billion |
Current Assets | $6.83 Billion |
Liabilities And Equity | $28.31 Billion |
Assets | $28.31 Billion |
Liabilities | $11.95 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Other Current Liabilities | $4.71 Billion |
Other Non-current Assets | $8.47 Billion |
Equity | $16.36 Billion |
Noncurrent Liabilities | $6.53 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Related Companies
View additional S&P 500 companies similar to Biogen Inc. Common Stock (BIIB)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.